A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Conditions

• Relapsed/Refractory Non-Hodgkin Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• BMS-986458 — DRUG
  Specified dose on specified days.
• Rituximab — DRUG
  Specified dose on specified days.
• Glofitamab/Obinutuzumab — DRUG
  Specified dose on specified days
• Mosunetuzumab — DRUG
  Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

Key Dates

Start date

Dec 29, 2023

Status verified

Apr 2026

Primary completion

Oct 28, 2027

Completion

Oct 28, 2028

Study Design

Enrollment

308 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Part A1
  Single Agent
• Experimental: Part A2
  Combination Treatment
• Experimental: Part B1
  Single Agent
• Experimental: Part B2
  Combination Treatment

Primary Outcome Measure

Number of participants with adverse events (AEs) [ Time Frame: Up to 2 years and 1 month ]

Central Contacts

• BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  855-907-3286
  [email protected]
• First line of the email MUST contain NCT # and Site #.

Locations (14)

Find similar trials in Phoenix, AZ